Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.38) by 15.79 percent. This is a 31.91 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $1.63 million which beat the analyst consensus estimate of $1.14 million by 42.69 percent. This is a 15.38 percent decrease over sales of $1.93 million the same period last year.